The global orthobiologics market is predicted to reach $6.06 billion by 2022, growing at a compounded annual rate of 5.4 percent.
Here are six things to know:
1. Increasing incidence of sports injuries and spinal fusions surgeries, as well as growing minimally invasive procedure market, are factors driving the orthobiologics market.
2. High cost pertaining to orthobiologics base treatment is a major factor restricting market growth.
3. Based on product, the viscosupplementation products segment is expected to account for the largest segment of the market due to increasing incidence of osteoarthritis.
4. Based on application, the osteoarthritis and degenerative arthritis segment is estimated to command the largest share of the orthobiologics market.
5. North America is predicted to account for the largest share of the global market.
6. Key players in the market include DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical and NuVasive.